Probiotics

Live microorganisms (bacteria and yeast) that, when administered in the right amounts, confer host microbiota-targeted health benefits.

LUX TAKE:

Probiotics will continue to garner attention, given their potential to impact multiple application areas. Expect to see more investment activities around the probiotics space by players both upstream and downstream in the food value chain in a bid to expand their health and wellness offerings. Applications beyond gut health, such as skin health and mood modulation, are gaining momentum but need ...

Lux Take last updated on July 17, 2020
Data last updated on October 15, 2020

What's New

Lux Research analysts and the Lux Intelligence Engine have added the following recent probiotics developments.

News Commentaries

Sun Genomics raises $8.65 million Series A for personalized probiotics (July 2, 2020)

DSM becomes the leader in the mycotoxin risk management market through $1.01 billion deal with Erber Group (June 12, 2020)

New Lux Content

Pebble Labs (September 28, 2020)

Locus Fermentation Solutions (September 1, 2020)

New Patents

Computing...

New Investment Rounds

Computing...

Related companies	Ganeden, ProGel, OptiBiotix, PRO-Hydro Beverages, Inc., Xtend Release, AB-Biotics, S-Biomedic, NextFoods, Inc., Hidoc Technologies, DoseBiome, Thryve, Biohm, Fitbiomics, ZBiotics, PERKii, Evolve BioSystems, Yofix Probiotics, Yun Probiotherapy

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Interested in Learning More?

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978